WEF25: Saudi Arabia “Rewriting the Economic Playbook”
24.1.2025 11:00:00 CET | Business Wire | Press release
Saudi Arabia’s delegation to the World Economic Forum (WEF) Annual Meeting today shared its strategy for rewriting the economic playbook during several key sessions, including one led by the Kingdom on its economic transformation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250124094652/en/
His Excellency Faisal F. Alibrahim, Minister of Economy and Planning (Photo: AETOSWire)
In the session titled ‘Saudi Arabia’s Economic Shifts’, His Excellency Mohammed A. Aljadaan, Minister of Finance, described the main forces driving the Kingdom’s transformation: “The whole nation has been mobilized behind Saudi Vision 2030. There’s a very clear vision that the people, the business community, and the government are all driving towards. We have a leadership that takes a long-term view, prepared to make tough decisions, and to be consistent.”
Earlier, in ‘The Road Ahead for Scaling AI’, His Excellency Abdullah A. Alswaha, Minister of Communications and Information Technology, outlined the Kingdom’s efforts to foster global dialogue to drive inclusive progress. He said: “The Kingdom today, in Davos, is working with like-minded partners, innovators and policymakers to see how we can leverage our competitive advantage and our position to serve humanity and fuel the AI economy in this age.”
His Excellency Bandar I. Alkhorayef, Minister of Industry and Mineral Resources, participated in the session ‘Next-Gen Industrial Infrastructure’. He said: “Today what we are doing in Saudi Arabia, in terms of our aspiration to diversify our economy, can be enabled with technology. Through the efforts of the government today, it is very clear we are prioritizing digital infrastructure and connectivity. We believe manufacturing is an important sector for growing the economy and we are committed to building the technologies that will shape its future.”
His Excellency Faisal F. Alibrahim, Minister of Economy and Planning: “We’re all seeking engines of growth. The Kingdom’s story is an example of how transformation is an engine of growth. Despite the tepid twenties, the Kingdom has been able to fire up new engines of growth and keep moving forward.”
The Royal Commission for Jubail and Yanbu (RCJY) announced that Jubail Industrial City has become the first city in the region to join WEF’s Transitioning Industrial Clusters to Sustainable Development initiative. Launched by WEF at Davos 2025 in collaboration with Accenture and the Electric Power Research Institute (EPRI), the initiative aims to accelerate the decarbonization of industrial clusters.
The Research, Development, and Innovation Authority has published a special report on the “Saudi Arabia’s Markets of Tomorrow Accelerator”. An initiative launched in collaboration with WEF’s Accelerator Network. The report highlights the initiative’s efforts to drive economic transformation through innovative, entrepreneurship-focused solutions, while outlining its vision for fostering the growth of key emerging markets in the Kingdom. It also explores how the initiative is tackling challenges and accelerating development to align with the goals of Saudi Vision 2030.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250124094652/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom